Print
|
Close
Grant C. Lewis MD
Summit Cancer Care
www.summitcancercare.com
Education and Training
Specialty and Certification
Medical Oncology, Hematology / Board Certified
Clinical Trial Cancer Types
Breast Cancer, Gynecologic Cancers, Head and Neck Cancer, Hematopoietic Malignancies, Leukemia, Lung Cancer, Melanoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Ovarian Cancer, Plasma cell neoplasm, Primary Peritoneal Cancer, Prostate Cancer , Quality of Life, Solid Tumor
Affiliations
Memorial University Medical Center
St. Joseph's/Candler
Hospital
Summit Cancer Care
Active Clinical Trial Sites in Georgia
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
4700 Waters Avenue
Savannah, GA 31404
912-350-8490 (p)
www.memorialhealth.com/anderson-cancer-institute.aspx
driving directions
Clinical Trials
DeKalb Surgical Associates - Northside
980 Johnson Ferry Road, NE
Suite 430
Atlanta, GA 30342
404-508-4320 (p)
404-508-4112 (f)
www.dekalbsurgical.com
driving directions
Clinical Trials
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
225 Candler Drive
Savannah, GA 31405
912-819-5704 (p)
www.sjchs.org
driving directions
Clinical Trials
Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
Cancer Type: Breast Cancer
Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer
Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Breast Cancer
Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy
Cancer Type: Breast Cancer
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Cancer Type: Breast Cancer
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Breast Cancer
Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Breast Cancer
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Breast Cancer
Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Breast Cancer
Adding an Immunotherapy Drug, MEDI4736 (durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Cancer Type: Breast Cancer
An Internet-based Program to Help Cancer Survivors Manage Pain (IMPACTS)
Cancer Type: Cancer Control
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Gynecologic Cancers
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Hematopoietic Malignancies
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Leukemia
Financial Difficulty in Patients with Blood Cancer
Cancer Type: Leukemia
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer
Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)
Cancer Type: Lung Cancer
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Cancer Type: Lung Cancer
Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer
Cancer Type: Lung Cancer
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Lung Cancer
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Lung Cancer
Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients who are PD-L1 Negative
Cancer Type: Lung Cancer
Non-Chemotherapy Treatment (Ramucirumab plus Pembrolizumab) or Standard Chemotherapy for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Trial
Cancer Type: Lung Cancer
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer that has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Cancer Type: Lung Cancer
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Melanoma
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cancer Type: Melanoma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Multiple Myeloma
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Multiple Myeloma
Financial Difficulty in Patients with Blood Cancer
Cancer Type: Multiple Myeloma
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Non-Hodgkin Lymphoma
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Ovarian Cancer
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Cancer Type: Plasma cell neoplasm
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Plasma cell neoplasm
Financial Difficulty in Patients with Blood Cancer
Cancer Type: Plasma cell neoplasm
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Primary Peritoneal Cancer
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Prostate Cancer
Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Prostate Cancer
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Type: Quality of Life
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol
Cancer Type: Solid Tumor
National Cancer Institute “Cancer Moonshot Biobank”
Cancer Type: Solid Tumor
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Solid Tumor
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Cancer Type: Solid Tumor
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
Cancer Type: Solid Tumor
Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Solid Tumor
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
Cancer Type: Solid Tumor
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Cancer Type: Solid Tumor
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Unknown Primary
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type: Unknown Primary
Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type: Unknown Primary
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Unknown Primary
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type: Unknown Primary
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type: Unknown Primary
Two Studies for Patients with High Risk Prostate Cancer Testing Less Intense Treatment for Patients with a Low Gene Risk Score and Testing a More Intense Treatment for Patients with a High Gene Risk Score, The PREDICT-RT Trial
Cancer Type: Unknown Primary
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type: Unknown Primary
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type: Unknown Primary
Use of a Genomic Tumor Board to Increase the Number of Patients with Recurrent, Refractory, Metastatic, or Newly Diagnosed Advanced Solid Tumors who Receive Genome-Informed Treatment
Cancer Type: Unknown Primary
Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial
Cancer Type: Unknown Primary
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type: Unknown Primary
Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type: Unknown Primary
Summit Cancer Care - Statesboro
16741 Highway 67 South
Suite B
Statesboro, GA 30458
912-871-8837 (p)
www.summitcancercare.com
driving directions
Clinical Trials
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
225 Candler Drive
Suite 300
Savannah, GA 31405
912-354-6187 (p)
www.summitcancercare.com
driving directions
Clinical Trials
Active Clinical Trial Site Locations:
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please
contact us
.